Table 5.
Outcome Associated with Pre-emptive Therapya for Upper Respiratory Illness in 12 Adult Bone Marrow Transplant Recipients with Respiratory Syncytial Virus Infections
| Time After Transplant |
|||
|---|---|---|---|
| ≤1 Month (n = 7) | >1 to ≤2 Months (n = 2) | >2 Months (n = 3) | |
| Resolution of illness | 5 | 2 | 3 |
| Progression to pneumonia | 2 | 0 | 0 |
a
Therapy consisted of aerosolized ribavirin and intravenous immunoglobulin (500 mg/kg every other day). Aerosolized ribavirin was administered at a dose of 20 mg/mL for 18 h/day to 5 patients (one of whom developed pneumonia and died) and a dose of 60 mg/mL for 2 h every 8 h to 7 patients (one of whom developed pneumonia and died).